Jiangsu pharmaceutical industry presents an agglomeration effect to form four major sectors

On the 25th, it was learned from the Jiangsu Provincial Food and Drug Administration that the development of the pharmaceutical industry in Jiangsu showed an agglomeration effect, and several very distinctive and compelling “medical sectors” have initially formed. They are Taizhou, Suzhou and Wuxi, Lianyungang and Nanjing Pukou.

It is understood that Taizhou City is currently actively creating the "China's First City of Medicine," accounting for one-third of the province's pharmaceutical economy, with an average annual growth rate of more than 50%. It is a well-known pharmaceutical industry gathering place in China and is sold by the Yangtze River Pharmaceutical Group. Revenue, profits and taxes, and comprehensive indicators ranked first in the industry for two consecutive years. In the pharmaceutical industry in Suzhou and Wuxi, the rapid development of foreign-funded enterprises is a significant feature. A group of internationally renowned pharmaceutical companies have settled down in Suzhou, among which GSK plans to invest a total of US$230 million and is currently the largest foreign-invested pharmaceutical company in China. Wuxi City facilitated the establishment of 10 foreign and domestic pharmaceutical companies to settle in the city through investment promotion. It has formed 3 pharmaceutical enterprise-intensive areas such as New District Pharmaceutical Industrial Park, Mashan Biological Medicine Industrial Park and Huishan Life Science Park. Nanjing Pukou Economic Development Zone is backed by universities and scientific research institutes. At present, there are a number of biopharmaceutical companies including Xiansheng Dongyuan, Saierjin, Zhongmai Science and Technology and Laoshan Pharmaceutical. Lianyungang has emerged a number of key production-oriented enterprises such as Hengrui Group, Kangyuan Pharmaceuticals, and Chia Tai Tianqing. It has built an industrial base consisting of new synthetic drugs and new-type Chinese medicines, and new anti-tumor drugs and new liver disease drugs produced by base companies. As well as the new dosage form of traditional Chinese medicine, it is in the leading position in the country.

According to the latest statistics, there are 16 companies in Jiangsu and 13 companies in the country that are short-listed in the national pharmaceutical industry sales revenue and the top 100 profit. Yangzijiang Pharmaceutical Co., Ltd. takes the top spot in the country, GlaxoSmithKline Pharmaceuticals (Suzhou) Co., Ltd., and Nanjing Pharmaceutical. Industrial (Group) Co., Ltd. and Jiangsu Hengrui Pharmaceutical Co., Ltd. entered the top 30 in the country.

Giga Series

ChongQing ChangHui Automotive parts Co.,ltd , https://www.cqchauto.com